Planta Med 2015; 81(12/13): 1141-1145
DOI: 10.1055/s-0035-1545979
Natural Product Chemistry
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

GPR18 Inhibiting Amauromine and the Novel Triterpene Glycoside Auxarthonoside from the Sponge-Derived Fungus Auxarthron reticulatum [*]

Autor*innen

  • Mamona Nazir

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
  • Henrik Harms

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
  • Irene Loef

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
  • Stefan Kehraus

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
  • Fayrouz El Maddah

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
  • Idris Arslan

    2   Pamukkale University, Biomedical Engineering, Denizli, Turkey
  • Viktor Rempel

    3   Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
  • Christa E. Müller

    3   Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
  • Gabriele M. König

    1   Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
Weitere Informationen

Publikationsverlauf

received 12. März 2015
revised 30. März 2015

accepted 31. März 2015

Publikationsdatum:
08. Mai 2015 (online)

Abstract

The marine sponge-derived fungus Auxarthron reticulatum produces the cannabinoid receptor antagonist amauromine (1). Recultivation of the fungus to obtain further amounts for more detailed pharmacological evaluation of 1 additionally yielded the novel triterpene glycoside auxarthonoside (2), bearing, in nature, a rather rare sugar moiety, i.e., N-acetyl-6-methoxy-glucosamine. Amauromine (1), which inhibited cannabinoid CB1 receptors (Ki 0.178 µM) also showed antagonistic activity at the cannabinoid-like orphan receptor GPR18 (IC50 3.74 µM). The diketopiperazine 1 may thus serve as a lead structure for the development of more potent and selective GPR18 antagonists, which are required to study the orphan receptorʼs potential as a new drug target. Despite the execution of many biological assays, to date, no bioactivity could be found for auxarthonoside (2).

* Dedicated to Professor Dr. Dr. h. c. mult. Adolf Nahrstedt on the occasion of his 75th birthday.